Open access
Open access
Powered by Google Translator Translator

Pediatrics – Allergy and Immunology

In a study with 1110 children with prolonged fever, MRP8/14 serum levels were validated as a diagnostic marker for systemic juvenile idiopathic arthritis.

14 Jan, 2022 | 08:07h | UTC

MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever – Rheumatology (link to abstract – $ for full-text)

Commentary: It is about time: the first validated biomarker for early diagnosis of sJIA – Rheumatology

 


RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function.

9 Dec, 2021 | 10:21h | UTC

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine

Commentary: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center

 


AAP Clinical Report: Biologics for Asthma and Allergic Skin Diseases in Children.

19 Nov, 2021 | 10:34h | UTC

Biologics for Asthma and Allergic Skin Diseases in Children – Pediatrics

 


An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

11 Nov, 2021 | 08:52h | UTC

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Related:

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

 


Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

4 Nov, 2021 | 10:00h | UTC

Ten Things to Know About MIS-C – American College of Cardiology

Related:

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

 


Podcast: Atopic Dermatitis Pearls.

27 Oct, 2021 | 01:01h | UTC

Atopic Dermatitis Pearls – The Cribsiders

 


Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

12 Sep, 2021 | 21:54h | UTC

One-Year Outcomes of Critical Care Patients Post–COVID-19 Multisystem Inflammatory Syndrome in Children – JAMA Pediatrics

Commentary: Outcome Good at One Year for Majority of PIMS-TS Patients – HealthDay

 

Commentary on Twitter

 


Kids and COVID: why young immune systems are still on top.

7 Sep, 2021 | 21:46h | UTC

Kids and COVID: why young immune systems are still on top – Nature

 


Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

3 Aug, 2021 | 09:05h | UTC

Six Month Follow-up of Patients With Multisystem Inflammatory Syndrome in Children – Pediatrics (PDF)

 


Experts recommend Covid jabs for some under-18s in UK – “advice is that 16 to 18-year-olds can be offered a Pfizer jab if they are in a priority group or live with someone who has a weakened immune system”.

20 Jul, 2021 | 10:15h | UTC

Commentaries: Experts recommend Covid jabs for some under-18s in UK – BBC

See report: JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years: 15 July 2021 – Joint Committee on Vaccination and Immunisation

 


New Zealand children falling ill in high numbers due to Covid ‘immunity debt’.

14 Jul, 2021 | 11:16h | UTC

New Zealand children falling ill in high numbers due to Covid ‘immunity debt’ – The Guardian

Related: New Zealand, where Covid-19 is dormant, fights another respiratory virus – The New York Times


CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.

24 Jun, 2021 | 09:51h | UTC

CDC safety group says there’s a likely link between rare heart inflammation in young people after Covid shot – CNBC

See also: Experts: mRNA COVID-19 vaccines likely tied to heart inflammation – CIDRAP

Related: Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination. AND CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.

 


Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

18 Jun, 2021 | 08:36h | UTC

Treatment of Multisystem Inflammatory Syndrome in Children – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics

Commentaries: Steroids may be effective treatment for COVID-19 complications in children – Imperial College London AND Expert reaction to study looking at treatments for COVID-19 complications in children – Science Media Centre

 


Audio Interview: potential treatments for children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19.

18 Jun, 2021 | 08:33h | UTC

Audio Interview: Covid-19 in Children – New England Journal of Medicine

 


Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

18 Jun, 2021 | 08:35h | UTC

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics

 


Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.

17 Jun, 2021 | 09:43h | UTC

Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings – JACC: Cardiovascular Imaging

Commentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology

Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.

 


Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.

17 Jun, 2021 | 09:45h | UTC

Myocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation

Commentary: Study details the treatment of COVID-19 vaccine-associated myocarditis-like illness in 7 patients – News Medical

Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.

 


Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.

17 Jun, 2021 | 09:41h | UTC

Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination – Pediatrics

Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.

 


Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

14 Jun, 2021 | 08:48h | UTC

Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 – JAMA Network Open

Commentary: MIS-C Incidence 316 Persons Per 1 Million SARS-CoV-2 Infections – HealthDay

 

Commentary on Twitter

 


Synopsis | Updates to the Pediatrics Asthma Management Guidelines.

8 Jun, 2021 | 09:22h | UTC

Updates to the Pediatrics Asthma Management Guidelines – JAMA Pediatrics (free for a limited period)

Original Guideline: 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group

 


Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

3 Jun, 2021 | 11:06h | UTC

6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study – The Lancet Child & Adolescent Health

Commentary: Most severe effects of MIS-C in children typically resolve within six months, new research suggests – CNN AND Children who developed a rare inflammation disease after COVID-19 are mostly better after 6 months, but some still suffer fatigue and anxiety, a small UK study found – Insider AND Most severe effects of PIMS-TS resolved at six months – HealthDay

 

Commentary on Twitter

 


ERS clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years.

20 May, 2021 | 08:21h | UTC

European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years – European Respiratory Journal

 


Systematic review: Combination fixed‐dose beta-agonist and steroid inhaler as required is clinically effective in adults and adolescents with mild asthma.

14 May, 2021 | 08:23h | UTC

Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library

Summary: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library

 


RCT: Tezepelumab can reduce exacerbations in adults and adolescents with severe, uncontrolled asthma.

14 May, 2021 | 08:25h | UTC

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma – New England Journal of Medicine

Commentary: New drug shows promise against tough-to-manage asthma – MedicalXpress

 


RCT: Tympanostomy-tube placement does not reduce episodes of acute otitis media among children 6 to 35 months of age with recurrent acute otitis media

13 May, 2021 | 05:57h | UTC

Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media – New England Journal of Medicine

Commentary: No lasting benefit to tubes over antibiotics for childhood ear infections – University of Pittsburgh

 


Stay Updated in Your Specialty

No spam, just news.